PL84227B1 - - Google Patents
Download PDFInfo
- Publication number
- PL84227B1 PL84227B1 PL1971174911A PL17491171A PL84227B1 PL 84227 B1 PL84227 B1 PL 84227B1 PL 1971174911 A PL1971174911 A PL 1971174911A PL 17491171 A PL17491171 A PL 17491171A PL 84227 B1 PL84227 B1 PL 84227B1
- Authority
- PL
- Poland
- Prior art keywords
- group
- ch2oh
- carbon atoms
- hydrochloride
- formula
- Prior art date
Links
- -1 3,4 -methylene Chemical group 0.000 claims description 11
- 125000004432 carbon atom Chemical group C* 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 7
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 150000002825 nitriles Chemical class 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical class [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 125000003302 alkenyloxy group Chemical group 0.000 claims description 2
- 125000000304 alkynyl group Chemical group 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 description 15
- SSOLNOMRVKKSON-UHFFFAOYSA-N proguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1 SSOLNOMRVKKSON-UHFFFAOYSA-N 0.000 description 14
- 239000002253 acid Substances 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000008298 dragée Substances 0.000 description 3
- 150000002431 hydrogen Chemical group 0.000 description 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- JFUBFTVIDOXELL-UHFFFAOYSA-N 2-(3-amino-2-hydroxypropoxy)benzonitrile Chemical compound NCC(O)COC1=CC=CC=C1C#N JFUBFTVIDOXELL-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
- YIUIVFFUEVPRIU-UHFFFAOYSA-N 8-chlorotheophylline Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21 YIUIVFFUEVPRIU-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- FWPKNCITVSFMKL-UHFFFAOYSA-N C(#C)C1=C(OC(C(CC(CO)(C)C)O)N)C=CC=C1 Chemical compound C(#C)C1=C(OC(C(CC(CO)(C)C)O)N)C=CC=C1 FWPKNCITVSFMKL-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 238000005642 Gabriel synthesis reaction Methods 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- VJMAITQRABEEKP-UHFFFAOYSA-N [6-(phenylmethoxymethyl)-1,4-dioxan-2-yl]methyl acetate Chemical compound O1C(COC(=O)C)COCC1COCC1=CC=CC=C1 VJMAITQRABEEKP-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002908 adrenolytic effect Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000005133 alkynyloxy group Chemical group 0.000 description 1
- 125000005336 allyloxy group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- WURBFLDFSFBTLW-UHFFFAOYSA-N benzil Chemical group C=1C=CC=CC=1C(=O)C(=O)C1=CC=CC=C1 WURBFLDFSFBTLW-UHFFFAOYSA-N 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940096529 carboxypolymethylene Drugs 0.000 description 1
- 229940097217 cardiac glycoside Drugs 0.000 description 1
- 239000002368 cardiac glycoside Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- XENVCRGQTABGKY-ZHACJKMWSA-N chlorohydrin Chemical compound CC#CC#CC#CC#C\C=C\C(Cl)CO XENVCRGQTABGKY-ZHACJKMWSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 229960001270 d- tartaric acid Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 150000003944 halohydrins Chemical class 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- BYXYCUABYHCYLY-UHFFFAOYSA-N isoindole-1,3-dione;potassium Chemical compound [K].C1=CC=C2C(=O)NC(=O)C2=C1 BYXYCUABYHCYLY-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 125000002560 nitrile group Chemical group 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229930002534 steroid glycoside Natural products 0.000 description 1
- 150000008143 steroidal glycosides Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C07D317/64—Oxygen atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Przedmiotem wynalazku jest sposób wytwarza¬ nia nowych l-fenoksy-2-hydroksy-3-hydroksyalkilo- aminopropanów, ich estrów i sali addycyjnych z kwasami. Nowe zwiazki wystepuja w postaci ra- cematów lub zwiazków optycznie czynnych.Nowym zwiazkom odpowiada wzór ogólny 1, w którym Ri oznacza grupe o wzorze (CH2)X—CN, (CH2)X—NH2 lub (CH2)x+i—OH (przy czym x oz¬ nacza liczbe calkowita 0—3), grupe o wzorze —COOR5 (przy czym R5 oznacza wodór lub grupe alkilowa o 1—4 atomach wegla), grupe alkenyIowa, alkenyloksylowa, alkinylowa lub alkinyloksylowa o 2—5 atomach wegla, R2 oznacza wodór, chloro¬ wiec, grupe alkilowa lub alkoksylowa o 1—4 ato¬ mach wegla, grupe alkenylowa o 2—5 atomach wegla, grupe nitrylowa lub nitrowa lub razem z Ri oznaczaja grupe 3,4-metylenodwuoksylowa, R3 oznacza wodór, chlorowiec lub grupe alkilowa wzglednie alkoksylowa o 1—4 atomach wegla i R4 oznacza prosta lub rozgaleziona grupe hydroksyal^ kilowa o 3—6 atomach wegla.Wedlug wynalazku nowe zwiazki wytwarza sie przez reakcje pierwszorzedowej aminy o wzorze ogólnym 2, w którym Rt—R3 maja wyzej podane znaczenie z halogenkiem hydroksyalkilowym, tozy- lanem lub mezylanem hydroksyalkilowym o wzorze ogólnym R4 —X, w którym R4 ma wyzej podane znaczenie, a X oznacza chlorowiec, grupe tozylowa lub mezylowa.Stosowane jako produkty wyjsciowe pierwszo- rzedowe aminy o wzorze 2 wytwarza sie z odpo¬ wiednich chlorowcohydryn przez reakcje z ftalimi- dem potasu i nastepnie rozszczepienie produktu reakcji za pomoca hydrazyny (tak zwana reakcja Gabriel'a).Otrzymywane sposobem wedlug wynalazku zwiaz ki posiadaja asymetryczny atom wegla w grupie CHOH i moga wystepowac w postaci racematu i optycznych antypodów. Te ostatnie mozna otrzy¬ mywac przez rozdzielenie racematu za pomoca zwykle stosowanych kwasów pomocniczych, takich jak kwas dwubenzoilo- /wzglednie dwu-p-toluilo- -/D-winowy lub kwas D-3-bromokamforo-8-sulfo- nowy oraz przez zastosowanie optycznie czynnych zwiazków wyjsciowych.Otrzymywane sposobem wedlug wynalazku 1-feno- ksy-2-hydroksy-3-hydroksyalkiloaminopropany o wzorze ogólnym 1 mozna w znany sposób przepro¬ wadzic w ich fizjologicznie dopuszczalne sole ad¬ dycyjne z kwasami. Odpowiednimi kwasami sa, np. kwas solny, bromowodorowy, siarkowy, metanosul- fonowy, maleinowy, winowy, octowy, szczawiowy, mlekowy lub 8-chloroteofilina. Przeprowadzanie ich w estry zachodzi równiez w znany sposób, np. przez reakcje z halogenkami acylowymi wzglednie z bezwodnikami acylowymi. Najbardziej uzywany¬ mi estrami jest 2-octan lub 2-propionian.Zwiazki o wzorze ogólnym 1 wzglednie ich fi¬ zjologicznie dopuszczalne sole addycyjne z kwasa¬ mi wykazuja w badaniach na swinkach morskich 8422784227 4 wartosciowe wlasciwosci ^-adrenolityczne, mozna je wiec stosowac do leczenia lub profilaktyki scho¬ rzen naczyn wiencowych i arytmii, w szczególnosci tachycardii, w medycynie. Równiez dzialanie ob¬ nizajace cisnienie krwi jest interesujace terapeu¬ tycznie. Zwiazki te wykazuja w stosunku do zna¬ nych zwiazków blokujacych ^-receptory, np. 1-(1- -naftyloksy)-2-hydroksy-3-izopropyloaminopropanu (propranololu) znacznie zmniejszone dzialanie tok¬ syczne.Szczególnie wartosciowymi okazaly sie zwiazki o wzorze 1, w którym R4 oznacza rozgaleziona gru¬ pe hydroksyalkilowa, zwlaszcza grupe 1,1-dwume- tylo-2-hydroksyetylowa. Dalej, w przypadku gdy Rj i R3 oznaczaja zwlaszcza wodór, jak równiez grupe alkilowa i Ri oznacza zwlaszcza nienasyco¬ na grupe, i.nls jak grupa etynylowa, nitrylowa, al- lilowa lub alliloksylowa ( w szczególnosci w polo¬ zeniu 2lancucha propanolu) lub grupe hydroksy- metjt^^]^^^^\pikie wykazuja bardzo szeroki zakres aktywnosci. Saczególnie wartosciowym pod wzgledem terapeutycznym jest l-(2-etynylofenoksy)- -2-hydroksy-3-(l,l-dwumetylo-2-hydroksyetylo)- -aminopropan i I-(2-cyjanofenoksy)-2-hydroksy-3- -(14-dwumetylo-2-hydroksyetylo)-aminopropan wzglednie fizjologicznie dopuszczalne sole addycyj¬ ne z kwasami i estry tych zwiazków. Szczególnie dobrze dzialaja równiez zwiazki, w których grupa fenylowa jest podstawiona w polozeniu 2 grupa ni¬ trylowa i równoczesnie nizsza grupa alkilowa, zwlaszcza grupa metylowa w polozeniu 5, np. l-(2- -cyjano-5-metylofenoksy)-2-hydroksy-3-(l,l-dwu- metylo-2-hydroksyetylo)-aminopropan lub jego so¬ le fizjologicznie dopuszczalne i estry.Dawka jednostkowa zwiazków otrzymywanych sposobem wedlug wynalazku wynosi 1—300 mg, zwlaszcza 5—100 mg (doustnie) wzglednie 1—20 mg (pozajelitowo).Nowe zwiazki mozna przerabiac w zwykle sto¬ sowane galcnowe formy uzytkowe, takie jak ta¬ bletki, drazetki, roztwory, emulsje, proszki, kapsul¬ ki lub srodki o przedluzonym dzialaniu w znany sposób, stosujac znane farmaceutyczne srodki po¬ mocnicze. Odpowiednio do tego tabletki mozna wytwarzac np. przez zmieszanie substancji czyn¬ nej z znanymi srodkami pomocniczymi, np. z obo¬ jetnymi srodkami rozcienczajacymi, jak weglan lub fosforan wapnia lub cukier mlekowy, srodkami rozkruszajacymi,. jak skrobia kukurydziana lub kwas alginowy, srodkami wiazacymi, jak skrobia lub zelatyna, srodkami nadajacymi poslizg, jak ste-* arynian magnezu lub talk i/lub srodkami powo¬ dujacymi przedluzone dzialanie, takimi jak karbo- ksypolimetylen, karboksymetyloceluloza, ftalan ace¬ tylocelulozy lub polioctan winylu.Tabletki moga równiez skladac sie z kilku warstw. Drazetki mozna wytwarzac przez powle¬ kanie rdzeni; otrzymanych tak jak tabletki, zwy¬ kle stosowanymi powlokami, np. z kolidonu lub szelaku, gumy arabskiej, talku, dwutlenku tytanu lub cukru. Dla osiagniecia efektu przedluzonego dzialania lub unikniecia niezgodnosci, rdzen moze sie skladac równiez z kilku warstw. Podobnie dla osiagniecia przedluzonego dzialania powloka dra- zetek moze sie skladac z kilku warstw, przy czym mozna stosowac wspomniane przy tabletkach srod¬ ki pomocnicze.Eliksiry zawierajace substancje czynna lub po¬ laczenie substancji czynnych moga zawierac do- datkowo srodek slodzacy, taki jak sacharyna, cy- klaminian, gliceryna lub cukier oraz. srodek polep¬ szajacy smak, np. substancje aromatyzujaca, jak wanilina lub ekstrakt pomaranczowy. Ponadto pre- paraty te moga zawierac srodki zawieszajace lub u zageszczajace, jak sól sodowa karboksymetyloce- lulozy, srodki zwilzajace, np. produkty kondensa¬ cji alkoholi tluszczowych z tlenkiem etylenu lub substancje konserwujaca jak prhydroksybenzeosan.Roztwory injekcyjne wytwarza sie w znany spo- sób z dodatkiem, np. srodka konserwujacego jak p-hydroksybenzoesan lub stabilizatora, jak kom- plekson. Roztworem takim napelnia sie ampulki lub fiolki injekcyjne.Kapsulki, zawierajace substancje czynna lub po- laczenie substancji czynnych, wytwarza sie np. przez zmieszanie substancji czynnej z obojetnym nosnikiem, takim jak cukier mlekowy lub sorbit i ta mieszanina napelnia sie kapsulki zelatynowe i zamyka.*• Czopki wytwarza sie np. przez zmieszanie sub¬ stancji czynnej lub substancji czynnych ze zwy¬ kle stosowanymi nosnikami, takimi jak obojetne tluszcze lub poligilikol etylenowy wzglednie jego- pochodne.Zwiazki otrzymywane sposobem wedlug wyna¬ lazku mozna stosowac w polaczeniu z innymi far- makodynamicznie dzialajacymi substancjami, np. srodkami rozszerzajacymi naczynia wiencowe, wy¬ wolujacymi efekt pobudzenia ukladu nerwowego 40 wspólczulnego, glikozydami nasercowymi lub srod¬ kami uspokajajacymi.Nastepujacy przyklad wyjasnia blizej wynalazek nie ograniczajac jego zakresu.Przyklad. Chlorowodorek l-(2-cyjanofeno- 45 ksy)-2-hydroksy-3-(2-metylo-2-hydroksyetylo)-ami- nopropanu. Mieszanine z 0,3 g (okolo 0,0015 mola) l-(2-cyjanofenoksy)-2-hydroksy-3-aminopropanu, 5 ml absolutnego alkoholu, 0,21 g (0,002 mola) sody, mg KJ i 0,189 g (0,002 mola) piopylenochlioriohy- 50 dryny ogrzewa sie do wrzenia, mieszajac przez 20 godzin. Chromatogram cienkowarstwowy pozada¬ nej substancji wykazuje, ze jej tworzenie sie jest po 20 godzinach zakonczone. Substancje te mozna po zwykle stosowanej obróbce przez oczyszczenie M na kolumnie z zelu krzemionkowego, uzyskac w stanie czystym. Chlorowodorek wytraca sie z al¬ koholowego roztworu przez dodanie eterowego roz¬ tworu HC1. Temperatura topnienia: 108/109-^111°C.Analogicznie mozna wytworzyc nastepujace •• zwiazki o wzorze 1:84227 Ri l 1 2—CN 2—CN 2—CN 2—O—CH2— —CH=CH2 2—C=OH 2—O—CH2— —CH=CH2 2—O—CH2— —CH=CH2 2—CH2—C=CH 2—CH2—C=CH 2—C=CH 2—CN 2—CH2—C=CH 2—CH2—CH= =CH2 2—CN 4—COOH 3—NH2 4—NH2 ' 2—OCH3 3,4—O—CH2—O 4—COOH 3—NH2 4—NH2 3,4—O—CH2—O- 2—NH2 2—NH2 2—OCH3 2—COOCH3 2—COOCH3 2—CH2OH 2—CH2OH 3—CH2OH 3—CH2OH 2—CN R2 2 H H —CH3 H H H H H H H —CH3 H H 4—Cl H H H 4—CN H H H H H 4—CN H H H H H H 4—CI R3 3_ H H H H H H H H H H H H H H H H H H H H H H H H H H H H H H H H H R4 , 4 ¦ . | —C(CH8)2—CH2OH —CH(C2H5)—CH2OH —C(CHS)2—CH2OH —CCCHsJg—CH2OH —C(CH3)2—CH2OH —CHg—CHOH—CH3 —CH(CH3)—CH2OH —C(CH3)2—CH2OH —CH(CH8)—CH2OH —CH(CH3)—CH2OH —CH2—CHOH—CH3 —CH(C2H5)—CH2OH —C —C(CH3)2—CH2OH —CH(CH8)—CH2Oli —CH(CH3)—CH2OH —CH(CH3)—CH2OH —CH(CH3)—CH2OH —C —C(CH8)2—CH2OH —C(CH8)2—CH2OH —C(CH8)2—CH2OH —CH(CH8)—CH2OH —C(CH8)2—CH2OH —CH(CH8)—CH2OH —C(CH8)2—CH2OH —CH(CH8)—CH2OH —C(CH8)2—CH2OH —C(CH3)2—CH2OH —CH(CH3)—CH2OH —CH(CH3)—CH2OH —C(CH3)2—CH2OH —CH(CH8)—CH2OH Temperatura 1 topnienia °C f 132—134 (chlorowodorek) 106—108 (chlorowodorek) 193—196 (chlorowodorek) 76—79 (chlorowodorek) 139—141 (chlorowodorek) 82—85 (chlorowodorek) 105—106 63—66 (chlorowodorek) 81—84 89—91 (chlorowodorek) 143—147 (chlorowodorek) 78—81 63—64 102—103 168—169 (chlorowodorek) 142—143 196 ' s (chlorowodorek) 147 (chlorowodorek) 168 (szczawian) 168 ' (chlorowodorek) 123—124 93 - 110 205—207 (dwuchlorowodorek) 196—198 (dwuchlorowodorek) 128—129 (chlorowodorek) 81 96 olej olej olej olej 113—114 50 oksylowa, R8 oznacza wodór, chlorowiec lub gru¬ pe alkilowa albo alkoksylowa o 1—4 atomach we¬ gla i R4 oznacza prosta lub rozgaleziona grupe hydroksyalkilowa o 3—6 atomach wegla w posta¬ ci racematów i optycznych antypodów, znamienny 55 tym, ze amine o wzorze ogólnym 2, w którym Ri—R3 maja wyzej podane znaczenie, wprowadza sie w reakcje z halogenkiem, tozylanem lub me- zylanem hydroksyalkilowym o wzorze ogólnym , R4—X, w którym R4 ma wyzej podane znaczenie, 60 a X oznacza grupe tozylowa lub mezylowa i otrzy¬ many racemat ewentualnie rozdziela sie na op¬ tyczne antypody i/lub otrzymany zwiazek o wzo¬ rze 1 przeprowadza w sól addycyjna z kwasem "lub w ester. PL PL PL PL
Claims (1)
1. Zastrzezenie patentowe Sposób wytwarzania nowych l-fenoksy-2-hydro- ksy-3-hydroksyalMloammopropainów o wzorze gólnym 1, w którym Ri oznacza grupe o wzorach (CH2)x—CN, .(CH2)X—NH2 lub (CH2)X+1—OH, przy czym x oznacza liczbe calkowita 0—3, grupe o wzo¬ rze —COOR5, w którym R5 oznacza wodór lub grupe alkilowa o 1—4 atomach wegla), grupe al- kenylowa, alkinylowa, alkenyloksylowa lub alki- nyloksylowa o 2—5 atomach wegla, R2 oznacza wodór, chlorowiec, grupe alkilowa lub alkoksylo¬ wa o 1—4 atomach wegla, grupe alkenylowa o 2—5 atomach wegla, grupe nitrylowa lub nitrowa lub razem z Ri oznaczaja grupe 3,4-metylenodwu- ^84227 QCH2~CH0H-CH2-NH-R£ Wzór 1 OCH2-CHOH-CH2-NH2 Wzór 2 DN z-3, zam. 2541/76 Cena 10 zl PL PL PL PL
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19702048838 DE2048838A1 (de) | 1970-10-05 | 1970-10-05 | Neue 1 Phenoxy 2 hydroxy 3 hydroxyal kylaminopropane und Verfahren zu ihrer Her stellung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL84227B1 true PL84227B1 (pl) | 1976-03-31 |
Family
ID=5784228
Family Applications (10)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL1971174911A PL84227B1 (pl) | 1970-10-05 | 1971-10-04 | |
| PL1971150902A PL82037B1 (pl) | 1970-10-05 | 1971-10-04 | |
| PL1971174908A PL84223B1 (pl) | 1970-10-05 | 1971-10-04 | |
| PL1971174909A PL84267B1 (pl) | 1970-10-05 | 1971-10-04 | |
| PL1971174905A PL84226B1 (pl) | 1970-10-05 | 1971-10-04 | |
| PL1971174907A PL84224B1 (pl) | 1970-10-05 | 1971-10-04 | |
| PL1971174910A PL84396B1 (pl) | 1970-10-05 | 1971-10-04 | |
| PL1971174912A PL84276B1 (pl) | 1970-10-05 | 1971-10-04 | |
| PL1971174903A PL84212B1 (pl) | 1970-10-05 | 1971-10-04 | |
| PL1971174906A PL84225B1 (pl) | 1970-10-05 | 1971-10-04 |
Family Applications After (9)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL1971150902A PL82037B1 (pl) | 1970-10-05 | 1971-10-04 | |
| PL1971174908A PL84223B1 (pl) | 1970-10-05 | 1971-10-04 | |
| PL1971174909A PL84267B1 (pl) | 1970-10-05 | 1971-10-04 | |
| PL1971174905A PL84226B1 (pl) | 1970-10-05 | 1971-10-04 | |
| PL1971174907A PL84224B1 (pl) | 1970-10-05 | 1971-10-04 | |
| PL1971174910A PL84396B1 (pl) | 1970-10-05 | 1971-10-04 | |
| PL1971174912A PL84276B1 (pl) | 1970-10-05 | 1971-10-04 | |
| PL1971174903A PL84212B1 (pl) | 1970-10-05 | 1971-10-04 | |
| PL1971174906A PL84225B1 (pl) | 1970-10-05 | 1971-10-04 |
Country Status (26)
| Country | Link |
|---|---|
| JP (1) | JPS5710097B1 (pl) |
| AT (10) | AT318570B (pl) |
| AU (1) | AU469119B2 (pl) |
| BE (1) | BE773472A (pl) |
| BG (8) | BG18857A3 (pl) |
| CA (1) | CA1008866A (pl) |
| CH (11) | CH564516A5 (pl) |
| CS (2) | CS172950B2 (pl) |
| DE (1) | DE2048838A1 (pl) |
| DK (1) | DK130958B (pl) |
| ES (8) | ES395671A1 (pl) |
| FI (1) | FI55491C (pl) |
| FR (1) | FR2110230B1 (pl) |
| GB (1) | GB1364280A (pl) |
| HU (1) | HU163226B (pl) |
| IE (1) | IE35693B1 (pl) |
| IL (1) | IL37830A (pl) |
| NL (1) | NL174249C (pl) |
| NO (1) | NO132835C (pl) |
| PH (1) | PH9959A (pl) |
| PL (10) | PL84227B1 (pl) |
| RO (8) | RO62313A (pl) |
| SE (1) | SE383631B (pl) |
| SU (2) | SU419024A3 (pl) |
| YU (2) | YU35576B (pl) |
| ZA (1) | ZA716643B (pl) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4055658A (en) * | 1976-05-17 | 1977-10-25 | Mead Johnson & Company | Cyanomethylphenethanolamines |
| DE3248835A1 (de) * | 1981-06-23 | 1983-06-30 | American Hospital Supply Corp | Zusammensetzungen fuer die behandlung von glaukom |
| US4454154A (en) * | 1981-06-23 | 1984-06-12 | American Hospital Supply Corporation | Method for treating glaucoma by the topical administration of selectively metabolized beta-blocking agents |
| US4652584A (en) * | 1984-07-13 | 1987-03-24 | Mcneilab, Inc. | Acetylenic phenoxypropanol derivatives and pharmaceutical compositions for the treatment of hypertension |
| DE4422707A1 (de) * | 1994-06-29 | 1996-01-04 | Hoechst Ag | Verfahren zum Färben aminierter Cellulose-/Polyester-Mischgewebe mit faserreaktiven Dispersionsfarbstoffen |
| JP4934287B2 (ja) * | 2005-04-05 | 2012-05-16 | 花王株式会社 | 美白剤 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD45360A (pl) * | ||||
| CA945172A (en) * | 1969-02-21 | 1974-04-09 | Imperial Chemical Industries Limited | Alkanolamine derivatives |
-
1970
- 1970-10-05 DE DE19702048838 patent/DE2048838A1/de not_active Withdrawn
-
1971
- 1971-04-10 SE SE7112536*A patent/SE383631B/xx unknown
- 1971-09-30 SU SU1700834A patent/SU419024A3/ru active
- 1971-10-01 IL IL37830A patent/IL37830A/xx unknown
- 1971-10-01 CH CH424675A patent/CH564516A5/xx not_active IP Right Cessation
- 1971-10-01 CH CH424075A patent/CH583686A5/xx not_active IP Right Cessation
- 1971-10-01 CH CH423975A patent/CH583685A5/xx not_active IP Right Cessation
- 1971-10-01 CH CH424175A patent/CH584185A5/xx not_active IP Right Cessation
- 1971-10-01 CH CH424575A patent/CH563342A5/xx not_active IP Right Cessation
- 1971-10-01 CH CH424375A patent/CH563341A5/xx not_active IP Right Cessation
- 1971-10-01 CH CH1430971A patent/CH564507A5/xx not_active IP Right Cessation
- 1971-10-01 CH CH423875A patent/CH587223A5/xx not_active IP Right Cessation
- 1971-10-01 CH CH424275A patent/CH583687A5/xx not_active IP Right Cessation
- 1971-10-04 YU YU2505/71A patent/YU35576B/xx unknown
- 1971-10-04 PL PL1971174911A patent/PL84227B1/pl unknown
- 1971-10-04 CA CA124,290A patent/CA1008866A/en not_active Expired
- 1971-10-04 NL NLAANVRAGE7113581,A patent/NL174249C/xx not_active IP Right Cessation
- 1971-10-04 BG BG020286A patent/BG18857A3/xx unknown
- 1971-10-04 BG BG020291A patent/BG18859A3/xx unknown
- 1971-10-04 JP JP7778571A patent/JPS5710097B1/ja active Pending
- 1971-10-04 DK DK481671AA patent/DK130958B/da not_active IP Right Cessation
- 1971-10-04 BG BG020288A patent/BG18858A3/xx unknown
- 1971-10-04 NO NO3632/71A patent/NO132835C/no unknown
- 1971-10-04 PH PH12895A patent/PH9959A/en unknown
- 1971-10-04 BG BG20289A patent/BG19134A3/xx unknown
- 1971-10-04 PL PL1971150902A patent/PL82037B1/pl unknown
- 1971-10-04 ES ES395671A patent/ES395671A1/es not_active Expired
- 1971-10-04 PL PL1971174908A patent/PL84223B1/pl unknown
- 1971-10-04 GB GB4610371A patent/GB1364280A/en not_active Expired
- 1971-10-04 BG BG020285A patent/BG19133A3/xx unknown
- 1971-10-04 PL PL1971174909A patent/PL84267B1/pl unknown
- 1971-10-04 ZA ZA716643A patent/ZA716643B/xx unknown
- 1971-10-04 PL PL1971174905A patent/PL84226B1/pl unknown
- 1971-10-04 PL PL1971174907A patent/PL84224B1/pl unknown
- 1971-10-04 BG BG020290A patent/BG19793A3/xx unknown
- 1971-10-04 BG BG020287A patent/BG20100A3/xx unknown
- 1971-10-04 PL PL1971174910A patent/PL84396B1/pl unknown
- 1971-10-04 PL PL1971174912A patent/PL84276B1/pl unknown
- 1971-10-04 BE BE773472A patent/BE773472A/xx not_active IP Right Cessation
- 1971-10-04 PL PL1971174903A patent/PL84212B1/pl unknown
- 1971-10-04 FI FI2769/71A patent/FI55491C/fi active
- 1971-10-04 PL PL1971174906A patent/PL84225B1/pl unknown
- 1971-10-04 BG BG018670A patent/BG20338A3/xx unknown
- 1971-10-05 RO RO73336A patent/RO62313A/ro unknown
- 1971-10-05 CS CS4618A patent/CS172950B2/cs unknown
- 1971-10-05 RO RO7100073338A patent/RO62358A/ro unknown
- 1971-10-05 RO RO73334A patent/RO62356A/ro unknown
- 1971-10-05 AT AT735373A patent/AT318570B/de not_active IP Right Cessation
- 1971-10-05 AT AT735173A patent/AT318568B/de not_active IP Right Cessation
- 1971-10-05 AT AT859371A patent/AT318561B/de not_active IP Right Cessation
- 1971-10-05 AT AT735573A patent/AT318572B/de not_active IP Right Cessation
- 1971-10-05 CS CS7034A patent/CS172932B2/cs unknown
- 1971-10-05 AT AT735073A patent/AT318567B/de not_active IP Right Cessation
- 1971-10-05 AT AT734973A patent/AT318566B/de not_active IP Right Cessation
- 1971-10-05 AT AT734873A patent/AT318565B/de not_active IP Right Cessation
- 1971-10-05 RO RO68372A patent/RO61540A/ro unknown
- 1971-10-05 RO RO7100073339A patent/RO62359A/ro unknown
- 1971-10-05 AT AT734773A patent/AT318564B/de not_active IP Right Cessation
- 1971-10-05 IE IE1246/71A patent/IE35693B1/xx unknown
- 1971-10-05 FR FR7135823A patent/FR2110230B1/fr not_active Expired
- 1971-10-05 AT AT735273A patent/AT318569B/de not_active IP Right Cessation
- 1971-10-05 RO RO7100073335A patent/RO62357A/ro unknown
- 1971-10-05 RO RO7100073337A patent/RO62267A/ro unknown
- 1971-10-05 HU HUBO1319A patent/HU163226B/hu unknown
- 1971-10-05 AT AT735473A patent/AT318571B/de not_active IP Right Cessation
- 1971-10-05 AU AU34182/71A patent/AU469119B2/en not_active Expired
- 1971-10-05 RO RO7100073333A patent/RO62355A/ro unknown
-
1972
- 1972-02-17 ES ES399869A patent/ES399869A1/es not_active Expired
- 1972-02-17 ES ES399868A patent/ES399868A1/es not_active Expired
- 1972-02-17 ES ES399872A patent/ES399872A1/es not_active Expired
- 1972-02-17 ES ES399873A patent/ES399873A1/es not_active Expired
- 1972-02-17 ES ES399870A patent/ES399870A1/es not_active Expired
- 1972-02-17 ES ES399871A patent/ES399871A1/es not_active Expired
- 1972-02-17 ES ES399874A patent/ES399874A1/es not_active Expired
-
1973
- 1973-02-28 SU SU731888527A patent/SU677649A3/ru active
-
1975
- 1975-04-03 CH CH414475A patent/CH564515A5/xx not_active IP Right Cessation
-
1976
- 1976-12-06 CH CH1430971A patent/CH587227A5/xx not_active IP Right Cessation
-
1979
- 1979-02-02 YU YU236/79A patent/YU35577B/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK168535B1 (da) | 2,6-Dialkylphenylaminocarbonylmethyl-piperazinderivater, fremgangsmåde til fremstilling deraf, samt farmaceutisk præparat indeholdende disse derivater | |
| JPS6089474A (ja) | モルフイナン誘導体,その製造方法,及び該化合物を含有する抗腫瘍剤 | |
| HU186560B (en) | Process for producing pharmaceutically active new bracket-3-amino-propoxy-bracket closed-biaenzyl derivatives | |
| PL91560B1 (pl) | ||
| US3974156A (en) | 2-(Substituted anilino) methylmorpholine compounds | |
| US3558652A (en) | N-monosubstituted pyrrylaminoethanols | |
| US3637852A (en) | 1-phenoxy-2-hydroxy-3-isopropylamino-propanes and salts thereof | |
| PL84227B1 (pl) | ||
| US4144340A (en) | Basic substituted xanthine derivatives | |
| US4977153A (en) | 3-aminopropyloxyphenyl derivatives, pharmaceutical compositions containing them and method for the therapy of diseases | |
| US4395559A (en) | 2,3-Indoledione derivatives | |
| PL84398B1 (en) | 1-(2'-cyano-phenoxy)-2-hydroxy-3-ethylamino-propane and salts thereof[us3732277a] | |
| US4117131A (en) | Method of inhibiting gastric acid secretions with 2-(4-pyrimidinyl)thioacetamides | |
| US4084002A (en) | Pharmaceutical compositions containing a 1-phenoxy-2-hydroxy-3-alkynylamino-propane and method of use | |
| US4016202A (en) | 1-Phenoxy-2-hydroxy-3-alkynylamino-propanes and salts thereof | |
| US4220659A (en) | 1-Phenoxy-2-hydroxy-3-alkynylamino-propanes and salts thereof | |
| GB2051796A (en) | (3 - alkylamino - 2 - hydroxypropoxy)-furan - 2 - carboxylic acid anilides and physiologically tolerated acid addition salts thereof processes for their preparation and medicaments containing them | |
| GB1580227A (en) | Piperazine derivatives | |
| US4010158A (en) | 1-(2'-Ethynyl-phenoxy)-2-hydroxy-3-butylamino-propanes and salts | |
| NZ196928A (en) | 1-(cyano(acylamino)phenoxy)-3-alkylaminopropan-2-ols | |
| JPH02258749A (ja) | ポリヒドロキシベンジルオキシプロパノールアミン | |
| KR850000696B1 (ko) | 1-(아실아미노-아릴옥시)-2-하이드록시-3-알키닐-아미노프로판의 제조방법 | |
| US4442120A (en) | 1-Aryloxy-3-alkylamino-propan-2-ols | |
| KR790001909B1 (ko) | 1-아릴옥시-2-하이드록시-3-알키닐아미노프로판의 제조방법 | |
| KR850000698B1 (ko) | 1-(아실아미노-아릴옥시)-2-하이드록시-3-알키닐-아미노프로판의 제조방법 |